Trial Search Results
Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
This study (GS-US-312-0117) is a multicenter, 2-arm, double-blind, parallel-group extension study that is a companion study to Study GS-US-312-0116, to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control.
Stanford is currently not accepting patients for this trial.
- Drug: Idelalisib
Key Inclusion Criteria:
- Individuals in the primary Phase 3 study (Study GS-US-312-0116) who are compliant
- Tolerating primary study therapy
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study